↓ Skip to main content

How do you design randomised trials for smaller populations? A framework

Overview of attention for article published in BMC Medicine, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter
145 X users
facebook
2 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
74 Mendeley
citeulike
1 CiteULike
Title
How do you design randomised trials for smaller populations? A framework
Published in
BMC Medicine, November 2016
DOI 10.1186/s12916-016-0722-3
Pubmed ID
Authors

Mahesh K. B. Parmar, Matthew R. Sydes, Tim P. Morris

Abstract

How should we approach trial design when we can get some, but not all, of the way to the numbers required for a randomised phase III trial?We present an ordered framework for designing randomised trials to address the problem when the ideal sample size is considered larger than the number of participants that can be recruited in a reasonable time frame. Staying with the frequentist approach that is well accepted and understood in large trials, we propose a framework that includes small alterations to the design parameters. These aim to increase the numbers achievable and also potentially reduce the sample size target. The first step should always be to attempt to extend collaborations, consider broadening eligibility criteria and increase the accrual time or follow-up time. The second set of ordered considerations are the choice of research arm, outcome measures, power and target effect. If the revised design is still not feasible, in the third step we propose moving from two- to one-sided significance tests, changing the type I error rate, using covariate information at the design stage, re-randomising patients and borrowing external information.We discuss the benefits of some of these possible changes and warn against others. We illustrate, with a worked example based on the Euramos-1 trial, the application of this framework in designing a trial that is feasible, while still providing a good evidence base to evaluate a research treatment.This framework would allow appropriate evaluation of treatments when large-scale phase III trials are not possible, but where the need for high-quality randomised data is as pressing as it is for common diseases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 145 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Germany 1 1%
South Africa 1 1%
Unknown 70 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 36%
Student > Ph. D. Student 11 15%
Professor > Associate Professor 6 8%
Student > Master 6 8%
Other 6 8%
Other 11 15%
Unknown 7 9%
Readers by discipline Count As %
Medicine and Dentistry 25 34%
Mathematics 11 15%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Nursing and Health Professions 4 5%
Agricultural and Biological Sciences 2 3%
Other 11 15%
Unknown 16 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 84. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2023.
All research outputs
#504,474
of 25,366,663 outputs
Outputs from BMC Medicine
#382
of 3,993 outputs
Outputs of similar age
#10,380
of 429,054 outputs
Outputs of similar age from BMC Medicine
#9
of 68 outputs
Altmetric has tracked 25,366,663 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,993 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.5. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 429,054 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.